

Fig. 31 Adenocarcinoma de colon LoVo. Control.




Fig. 31a Adenocarcinoma de colon LoVo.

Doxorrubicina 1.6 mcgr/ml.




Fig. 32' Células de Chang. Control




Fig. 32a' Células de Chang. Epidoxorubicina 0.8 mcgr/ml.




Fig. 32 Hepatoma PLC/PRF/5. Control.




Fig. 32a Hepatoma PLC/PRF/5.

Epidoxorubicina 0.8 mcgr/ml.



Fig. 33' Células de Chang. Control




Fig. 33a' Células de Chang. Etoposida 0.8 mcgr/ml.




Fig. 33 Hepatoma Hep 3B. Control.




Fig. 33a Hepatoma Hep 3B. Epidoxorubicina 0.8 mcgr/ml.



Fig. 34' Células de Chang. Control




Fig. 34a' Células de Chang. Epidoxorubicina 0.8 mcgr/ml.




Fig. 34 Hepatoma Hep G2. Control.




Fig. 34a Hepatoma Hep G2. Epidoxorubicina 0.8 mcgr/ml.




Fig. 35' Células de Pulmón. Control




Fig. 35a' Células de Pulmón. Etoposida 0.8 mcgr/ml.




Fig. 35 Carcinoma broncogénico ChaGoK-1. Control.




Fig. 35a Carcinoma broncogénico ChaGoK-1.

Epodoxorubicina 0.8 mcgr/ml.




Fig. 36' Células de Pulmón. Control




Fig. 36a' Células de Pulmón. Epodoxorubicina 0.8 mcgr/ml.




Fig. 36 Adenocarcinoma pulmonar Calu-3. Control.




Fig. 36a Adenocarcinoma pulmonar Calu-3.  
Epidoxorubicina 0.8 mcgr/ml.




Fig. 37' Células de Pulmón. Control




Fig. 37a' Células de Pulmón. Epidoxorubicina 0.8 mcgr/ml.




Fig. 37 Carcinoma pulmonar de células escamosas SK-Mes-1.  
Control.




Fig. 37a Carcinoma pulmonar de células escamosas SK-Mes-1.  
Epidoxorubicina 0.8 mcgr/ml.




Fig. 38' Células de Pulmón. Control






Fig. 38a' Células de Pulmón. Epidoxorrubicina 0.8 mcgr/ml.



**Fig. 38 Carcinoma pulmonar de células pequeñas NCI-H69.  
Control.**



**Fig. 38a Carcinoma pulmonar de células pequeñas NCI-H69.  
Epidoxorubicina 0.8 mcgr/ml.**



Fig. 39' Células de Colon. Control




Fig. 39a' Células de Colon. Epidoxorubicina 0.8 mcgr/ml.




Fig. 39 Adenocarcinoma de Colon LoVo. Control.




Fig. 39a Adenocarcinoma de Colon LoVo.  
Epidoxorrubicina 0.8 mcgr/ml.

60'



Fig. 40' Células de Chang. Control





Fig. 40a' Células de Chang. Mitomicina 2 mcgr/ml.



**Fig. 40 Hepatoma PLC/PRF/5. Control.**



**Fig. 40a Hepatoma PLC/PRF/5. Mitomicina 2 mcgr/ml.**



Fig. 41' Células de Chang. Control




Fig. 41a' Células de Chang. Mitomicina 2 mcgr/ml.




Fig. 41 Hepatoma Hep 3B. Control.




Fig. 41a Hepatoma Hep 3B. Mitomicina 2 mcgr/ml.




Fig. 42' Células de Chang. Control




Fig. 42a' Células de Chang. Mitomicina 2 mcgr/ml.



Fig. 42 Hepatoma Hep G2. Control.




Fig. 42a Hepatoma Hep G2. Mitomicina 2 mcgr/ml.




Fig. 43' Células de Pulmón. Control




Fig. 43a' Células de Pulmón. Mitomicina 2 mcgr/ml.




Fig. 43 Carcinoma broncogénico ChaGoK-1. Control.




Fig. 43a Carcinoma broncogénico ChaGoK-1.  
Mitomicina 2 mcgr/ml.




Fig. 44' Células de Pulmón. Control




Fig. 44a' Células de Pulmón. Mitomicina 2 mcgr/ml.




Fig. 44 Adenocarcinoma pulmonar Calu-3. Control.




Fig. 44a Adenocarcinoma pulmonar Calu-3.

Mitomicina 2 mcgr/ml.




Fig. 45' Células de Pulmón. Control




Fig. 45a' Células de Pulmón. Mitomicina 2 mcgr/ml.